HAART with didanosine once versus twice daily: Adherence and efficacy

International Journal of Infectious Diseases

Volumn 9, Issue 4, 2005, Pages 195-200

  Roca, Bernardino ^a   Lapuebla, Consol ^a   Vidal Tegedor, Barbara ^a  

^a HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

Adherence; Antiretroviral therapy; CD4 cells; Drug users; Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHEMISTRY, PHARMACEUTICAL; COHORT STUDIES; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES;

EID: 20444450202     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2004.07.006     Document Type: Article

References (34)

1. S.M. Hammer, K.E. Squires, M.D. Hughes, J.M. Grimes, L.M. Demeter, and J.S. Currier A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less N Engl J Med 337 1997 725 733
2. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 1998 853 860
3. D. Bangsberg, J.P. Tulsky, F.M. Hecht, and A.R. Moss Protease inhibitors in the homeless JAMA 278 1997 63 65
4. B. Roca, C.J. Gómez, and A. Arnedo Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients J Infect 41 2000 50 54
5. C.C. Carpenter, D.A. Cooper, M.A. Fischl, J.M. Gatell, B.G. Gazzard, and S.M. Hammer Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel JAMA 283 2000 381 390
6. J. Kahn The clinical use of didanosine Adv Exp Med Biol 394 1996 245 256
7. B.D. Damle, S. Kaul, D. Behr, and C. Knupp Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects J Clin Pharmacol 42 2002 791 797
8. B.D. Damle, J.H. Yan, D. Behr, E. O'Mara, P. Nichola, and S. Kaul Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads J Clin Pharmacol 42 2002 419 427
9. B. Damle, H. Hess, S. Kaul, and C. Knupp Absence of clinically relevant drug interactions following simultaneous administration of didanosine- encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole Biopharm Drug Dispos 23 2002 59 66
10. L.M. Kunches, N.E. Reinhalter, A. Marquis, E. Coakley, C. Cohen, and A.B. Morris Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection J Acquir Immune Defic Syndr 28 2001 150 153
11. M.D. Kazatchkine, P.N. Van, D. Costagliola, A.S. Mohammed, J.M. Ledeine, and M. Troccaz Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy J Acquir Immune Defic Syndr 24 2000 418 424
12. F. García, H. Knobel, M.A. Sambeat, J. Arrizabalaga, M. Aranda, and J. Romeu Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. Spanish SCAN Study Group AIDS 14 2000 2485 2494
13. R.B. Pollard Didanosine once daily: potential for expanded use AIDS 14 2000 2421 2428
14. J. Gathe Jr., R. Badaro, A. Grimwood, L. Abrams, K. Klesczewski, and A. Cross Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir J Acquir Immune Defic Syndr 31 2002 399 403
15. Centers for Disease Control and Prevention Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents MMWR 47 RR-5 1998 1 41
16. C.C. Carpenter, M.A. Fischl, S.M. Hammer, M.S. Hirsch, D.M. Jacobsen, and D.A. Katzenstein Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel JAMA 277 1997 1962 1969
17. US Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Published online: http://www.hivatis.org. 28 January 2000.
18. R.M. Malow, S.M. Baker, N. Klimas, M.H. Antoni, N. Schneiderman, and F.J. Penedo Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers Psychiatr Serv 49 1998 1021 1024
19. L. Eldred, and L. Cheever Update on Adherence to HIV Therapy Hopkins HIV Rep Jan 1998 10 11
20. B. Roca, C.J. Gómez, and A. Arnedo A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment experienced HIV-infected patients AIDS 14 2000 157 161
21. B. Roca, C.J. Gómez, and A. Arnedo Stavudine, lamivudine and indinavir in drug users and non-drug users HIV-infected patients: adherence, side effects and efficacy J Infect 39 1999 141 145
22. I. Suárez-Lozano, J.M. Fajardo, M. Garrido, B. Roca, M.L. García-Alcalde, and P. Geijo Epidemiological trends of HIV infection in Spain: preventative plans have to be oriented to new target populations (Spanish VACH Cohort) AIDS 16 2002 2496 2499
23. D.L. Paterson, B. Potoski, and B. Capitano Measurement of adherence to antiretroviral medications J Acquir Immune Defic Syndr 31 2002 S103 S106
24. J.C. Walsh, S. Mandalia, and B.G. Gazzard Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome AIDS 16 2002 269 277
25. M.P. Carrieri, M.A. Chesney, B. Spire, A. Loundou, A. Sobel, and G. Lepeu Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users Int J Behav Med 10 2003 1 14
26. A.W. Wu, A. Ammassari, and A. Antinori Adherence to antiretroviral therapy: where are we, and where do we go from here? J Acquir Immune Defic Syndr 31 2002 S95 S97
27. N. Press, M.W. Tyndall, E. Wood, R.S. Hogg, and J.S. Montaner Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence J Acquir Immune Defic Syndr 31 2002 S112 S117
28. M.P. Trotta, A. Ammassari, S. Melzi, M. Zaccarelli, N. Ladisa, and L. Sighinolfi Treatment-related factors and highly active antiretroviral therapy adherence J Acquir Immune Defic Syndr 31 2002 S128 S131
29. K. Schroeder, T. Fahey, and S. Ebrahim Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings Cochrane Database Syst Rev 2 2004 CD004804
30. F. Maggiolo, M. Migliorino, R. Maserati, A. Pan, M. Rizzi, and G. Provettoni Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz Antivir Ther 6 2001 249 253
31. C. De Mendoza, V. Soriano, M. Pérez-Olmeda, R. Rodríguez-Rosado, and J. González-Lahoz Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients J Hum Virol 3 2000 335 340
32. US Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Published online: http://www.aidsinfo.nih.gov. 4 February 2002.
33. M. Guarinieri Highly active antiretroviral therapy adherence: the patient's point of view J Acquir Immune Defic Syndr 31 2002 S167 S169
34. A. Ammassari, M.P. Trotta, R. Murri, F. Castelli, P. Narciso, and P. Noto Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature J Acquir Immune Defic Syndr 31 2002 S123 S127